Literature DB >> 15047439

[Cryptococosis and HIV/AIDS: a review of 21 cases reported in the Tropical Diseases Centre, Ho Chi Minh City (Vietnam)].

Thi Xuan Tuyet Huynh1, Huu Chi Nguyen, Minh Quang Vo, Sophie Odermatt-Biays, Antoine Degrémont, Denis Malvy.   

Abstract

Cryptococcus neoformans affections during HIV-infection are frequent and serious. The aim of this study was to analyse the epidemiological, clinical, biological and therapeutic characteristics of cryptococcal meningitis in HIV-positive patients, admitted into the Center for Tropical Diseases Ho Chi Minh City (Vietnam), during a 5-month period (May-September 2001). Twenty-one patients (20 men and one woman) were included (identification of C. neoformans from the cerebrospinal fluid). The mean age was 28 years. The majority of patients had been living in Ho Chi Minh City (48%). The use of drugs and unprotected sexual relations were the principal risk factors of HIV-infection. The paucity and the confusion of clinical signs and symptoms, along with a high frequency of meningitis have been analysed. Clinical presentation features included: headache (95%), emaciation (90%), oro-pharyngeal candidiasis (90%), stiff neck (80%), nausea/vomiting (70%), fever (67%), coughing (38%), diarrhoea (33%), skin lesions (5%), convulsion (5%), photophobia (5%), and hemiparesis (5%). The severity of the prognosis was mainly linked to the delay before hospitalization, to the possible association with other opportunistic infections, and to the availability of appropriate treatment.

Entities:  

Mesh:

Year:  2003        PMID: 15047439

Source DB:  PubMed          Journal:  Sante        ISSN: 1157-5999


  1 in total

1.  Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.

Authors:  Rachel M Smith; Tuan Anh Nguyen; Hoang Thi Thanh Ha; Pham Hong Thang; Cao Thuy; Truong Xuan Lien; Hien T Bui; Thai Hung Le; Bruce Struminger; Michelle S McConnell; Robyn Neblett Fanfair; Benjamin J Park; Julie R Harris
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.